A 65-year-old woman with a FGFR3-TACC3 fusion-positive glioblastoma, diagnosed in 01/2020, received anlotinib after she had tumor progress following gross total resection and treatment with radiochemotherapy with temozolomide and five adjuvant cycles of temozolomide. This evidence concerns the gene TACC3 and neoplasm.